Key Highlights

  • Shareholders of both Kimberly-Clark Corporation and Kenvue Inc. overwhelmingly approved the deal.
  • The Acquisition is valued at roughly USD 48.7 billion.
  • Kenvue is the maker of Tylenol, among other consumer health brands.
  • Some regulatory risks remain ahead even as the deal heads toward completion.

Shareholders Give Overwhelming Approval

Shareholders of both Kimberly-Clark Corporation and Kenvue Inc., the maker of Tylenol and other well-known consumer health brands, overwhelmingly approved Kimberly-Clark's roughly USD 48.7 billion acquisition of Kenvue, clearing one of the most significant hurdles for a deal of this scale. Strong Shareholder approval on both sides of a transaction typically reflects broad confidence in the strategic rationale and terms of the deal among each company's respective investor base. At the January 29, 2026 vote, roughly 96 percent of Kimberly-Clark shares approved the stock issuance, while about 99 percent of votes cast on Kenvue's side, representing roughly 77 percent of outstanding shares, backed the deal. Kimberly-Clark CEO Mike Hsu said the combination advances the company's efforts to create a preeminent global health and wellness leader, with closing expected in the second half of 2026.

Creating a Global Health and Wellness Giant

The combination would bring together Kimberly-Clark's portfolio of household and personal-care products with Kenvue's consumer health brands, creating a combined company positioned as a global health and wellness giant spanning categories from tissue and diaper products to over-the-counter medications and skincare. A combination of this breadth is intended to create cross-selling opportunities and supply-chain efficiencies across what would become a considerably larger consumer products portfolio.

Regulatory Risks Still Ahead

Despite the strong shareholder approval, some regulatory risks remain ahead of final completion, reflecting the scrutiny that large consumer-products combinations typically face from antitrust regulators concerned about market concentration in specific product categories. The deal's ultimate close will likely depend on how regulators assess any overlap between the two companies' product lines and whether remedies are required to address specific competitive concerns.

Where Things Stand

The overwhelming shareholder approval from both Kimberly-Clark and Kenvue investors moves the USD 48.7 billion acquisition significantly closer to completion, even as some regulatory risks remain before the deal can formally close. The combined company would become a substantial global health and wellness player spanning a wide range of consumer product categories.